Connection

KIM-ANH DO to Adult

This is a "connection" page, showing publications KIM-ANH DO has written about Adult.
Connection Strength

0.275
  1. MicroRNAs are enriched at COVID-19 genomic risk regions, and their blood levels correlate with the COVID-19 prognosis of cancer patients infected by SARS-CoV-2. Mol Cancer. 2024 Oct 21; 23(1):235.
    View in: PubMed
    Score: 0.009
  2. Analysis of melanoma onset: assessing familial aggregation by using estimating equations and fitting variance components via Bayesian random effects models. Twin Res. 2004 Feb; 7(1):98-113.
    View in: PubMed
    Score: 0.009
  3. Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS. NEJM Evid. 2022 Oct; 1(10):EVIDoa2200034.
    View in: PubMed
    Score: 0.008
  4. A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression. J Clin Endocrinol Metab. 2021 11 19; 106(12):e4969-e4980.
    View in: PubMed
    Score: 0.008
  5. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Mod Pathol. 2022 04; 35(4):470-479.
    View in: PubMed
    Score: 0.008
  6. Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg. 2021 08 01; 274(2):e150-e159.
    View in: PubMed
    Score: 0.008
  7. Genetic analysis of the age at menopause by using estimating equations and Bayesian random effects models. Stat Med. 2000 May 15; 19(9):1217-35.
    View in: PubMed
    Score: 0.007
  8. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622.
    View in: PubMed
    Score: 0.007
  9. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019 08 08; 178(4):795-806.e12.
    View in: PubMed
    Score: 0.007
  10. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
    View in: PubMed
    Score: 0.007
  11. Demographic, clinical, and geographical factors associated with lack of receipt of physician recommended chemotherapy in women with breast cancer in Texas. Cancer Causes Control. 2019 Apr; 30(4):409-415.
    View in: PubMed
    Score: 0.006
  12. Predictive factors of age at menopause in a large Australian twin study. Hum Biol. 1998 Dec; 70(6):1073-91.
    View in: PubMed
    Score: 0.006
  13. Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: A randomized clinical trial. PLoS One. 2018; 13(11):e0205064.
    View in: PubMed
    Score: 0.006
  14. A System-Level Approach to Improve the Uptake of Antiestrogen Preventive Therapy among Women with Atypical Hyperplasia and Lobular Cancer In Situ. Cancer Prev Res (Phila). 2018 05; 11(5):295-302.
    View in: PubMed
    Score: 0.006
  15. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. 2018 04 19; 131(16):1820-1832.
    View in: PubMed
    Score: 0.006
  16. Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clin Cancer Res. 2017 Jun 15; 23(12):2991-3002.
    View in: PubMed
    Score: 0.005
  17. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016 09 01; 126(9):3363-76.
    View in: PubMed
    Score: 0.005
  18. Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2015; 10(9):e0136851.
    View in: PubMed
    Score: 0.005
  19. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst. 2015 Mar; 107(3).
    View in: PubMed
    Score: 0.005
  20. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7.
    View in: PubMed
    Score: 0.005
  21. Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. Breast Cancer Res Treat. 2014 Jan; 143(1):189-201.
    View in: PubMed
    Score: 0.004
  22. Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev. 2014 Feb; 23(2):316-23.
    View in: PubMed
    Score: 0.004
  23. Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy. Ann Oncol. 2013 Oct; 24(10):2522-2526.
    View in: PubMed
    Score: 0.004
  24. The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes. Oncologist. 2013; 18(5):493-500.
    View in: PubMed
    Score: 0.004
  25. Genetic variants in the vitamin D pathway and breast cancer disease-free survival. Carcinogenesis. 2013 Mar; 34(3):587-94.
    View in: PubMed
    Score: 0.004
  26. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res. 2012 Oct 26; 14(5):R138.
    View in: PubMed
    Score: 0.004
  27. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer. 2013 Jan 01; 119(1):7-15.
    View in: PubMed
    Score: 0.004
  28. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 2011 Nov 01; 29(31):4088-95.
    View in: PubMed
    Score: 0.004
  29. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer. 2012 Mar 15; 118(6):1498-506.
    View in: PubMed
    Score: 0.004
  30. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):2628-34.
    View in: PubMed
    Score: 0.004
  31. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011 Mar 01; 17(5):1082-9.
    View in: PubMed
    Score: 0.004
  32. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010 Aug; 3(8):1026-34.
    View in: PubMed
    Score: 0.004
  33. Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study. Thromb Haemost. 2010 Sep; 104(3):498-503.
    View in: PubMed
    Score: 0.003
  34. Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. Eur Urol. 2010 Jun; 57(6):1030-8.
    View in: PubMed
    Score: 0.003
  35. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):204-14.
    View in: PubMed
    Score: 0.003
  36. Polymorphisms in genes involved in neurodevelopment may be associated with altered brain morphology in schizophrenia: preliminary evidence. Psychiatry Res. 2009 Jan 30; 165(1-2):1-9.
    View in: PubMed
    Score: 0.003
  37. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol. 2008 Dec 20; 26(36):5936-42.
    View in: PubMed
    Score: 0.003
  38. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008 Aug 15; 112(4):975-80.
    View in: PubMed
    Score: 0.003
  39. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2007 Oct 10; 25(29):4648-56.
    View in: PubMed
    Score: 0.003
  40. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1224-31.
    View in: PubMed
    Score: 0.003
  41. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007 Jun 01; 109(11):4679-85.
    View in: PubMed
    Score: 0.003
  42. Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy. Leukemia. 2007 Mar; 21(3):480-8.
    View in: PubMed
    Score: 0.003
  43. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer. 2006 Aug 01; 107(3):497-505.
    View in: PubMed
    Score: 0.003
  44. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. J Clin Oncol. 2006 Aug 01; 24(22):3619-22.
    View in: PubMed
    Score: 0.003
  45. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006 Jul 01; 107(1):125-35.
    View in: PubMed
    Score: 0.003
  46. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006 May 20; 24(15):2343-51.
    View in: PubMed
    Score: 0.003
  47. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. Leuk Res. 2007 Feb; 31(2):139-45.
    View in: PubMed
    Score: 0.003
  48. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach? Urology. 2006 Mar; 67(3):466-71.
    View in: PubMed
    Score: 0.003
  49. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer. 2006 Jan 15; 106(2):337-45.
    View in: PubMed
    Score: 0.003
  50. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6889-94.
    View in: PubMed
    Score: 0.003
  51. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20; 23(18):4070-8.
    View in: PubMed
    Score: 0.002
  52. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004 Sep 01; 101(5):999-1008.
    View in: PubMed
    Score: 0.002
  53. Serum levels of insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):3988-95.
    View in: PubMed
    Score: 0.002
  54. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res. 2004 Jun; 28(6):595-604.
    View in: PubMed
    Score: 0.002
  55. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol. 2003 Dec; 123(5):850-7.
    View in: PubMed
    Score: 0.002
  56. Serum organochlorine levels and history of lactation in Egypt. Environ Res. 2003 Jun; 92(2):110-7.
    View in: PubMed
    Score: 0.002
  57. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol. 2003 Feb; 120(3):452-6.
    View in: PubMed
    Score: 0.002
  58. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer. 2002 May 20; 86(10):1555-60.
    View in: PubMed
    Score: 0.002
  59. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002 Mar 15; 20(6):1527-36.
    View in: PubMed
    Score: 0.002
  60. A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol Biomarkers Prev. 2002 Mar; 11(3):275-9.
    View in: PubMed
    Score: 0.002
  61. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl. 2002 Mar; 8(3):233-40.
    View in: PubMed
    Score: 0.002
  62. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial. Ann Oncol. 2002 Jan; 13(1):125-34.
    View in: PubMed
    Score: 0.002
  63. Racial disparity in survival of patients with squamous cell carcinoma of the oral cavity and pharynx. Ethn Health. 2001 Aug-Nov; 6(3-4):165-77.
    View in: PubMed
    Score: 0.002
  64. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001 Jul 01; 98(1):181-6.
    View in: PubMed
    Score: 0.002
  65. Reconstructive management of cranial base defects after tumor ablation. Plast Reconstr Surg. 2001 May; 107(6):1346-55; discussion 1356-7.
    View in: PubMed
    Score: 0.002
  66. Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg. 2001 May; 136(5):528-35.
    View in: PubMed
    Score: 0.002
  67. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery. 2000 May; 127(5):512-9.
    View in: PubMed
    Score: 0.002
  68. Birth weight and age at menopause in Australian female twin pairs: exploration of the fetal origin hypothesis. Hum Reprod. 2000 Jan; 15(1):55-9.
    View in: PubMed
    Score: 0.002
  69. Perceptual variation in grading hand, hip and knee radiographs: observations based on an Australian twin registry study of osteoarthritis. Ann Rheum Dis. 1999 Dec; 58(12):766-9.
    View in: PubMed
    Score: 0.002
  70. Predictors of hysterectomy: an Australian study. Am J Obstet Gynecol. 1999 Apr; 180(4):945-54.
    View in: PubMed
    Score: 0.002
  71. Functional analysis of IgA antibodies specific for a conserved epitope within the M protein of group A streptococci from Australian Aboriginal endemic communities. Int Immunol. 1999 Apr; 11(4):569-76.
    View in: PubMed
    Score: 0.002
  72. Correlation of the proliferative index of residual leukemia with outcome in patients treated with sequential high dose ara-C and asparaginase. Leukemia. 1990 May; 4(5):316-20.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.